Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 1999

View Archived Issues

Guilford: Q2 1999 highlights

Aronex will not present at September ODAC meeting

Therapeutic Antibodies submits PLA and ELA for DigiTAb

Incara receives milestone payment from Merck for antibacterial collaboration

Teva and Copley to merge

Genta makes strides with G-3139 in Q2 1999

MAb 1F7 making steady progress toward clinical testing stage

Bayer will begin clinical trials of IL-4 antagonist for asthma

Targeted Genetics: Q2 1999 results

Dual-action antihistamines/substance P antagonists from HMR

Ferrer patents novel series with a unique profile of activity

Ibutilide is effective in conversion of atrial arrhythmia secondary to cardiac surgery

Novo Nordisk signs GlucaGen marketing agreement with Bedford

Bioniche reports on MCC cancer therapy at British meeting

Nycomed Amersham acquires Magnetic Imaging Technologies

EMEA accepts Evacet filing

FDA puts hold on clinical study of Vasomax

Phase II trial commences for Alexion's C5 complement inhibitor in RA

Sparta stockholders approve acquisition by SuperGen

Metabolex and Iconix to collaborate on diabetes drug discovery

Phase II testing of Alexion's C5 complement inhibitor also begins in renal diseases

Three new clinical candidates enter the pipeline at Eisai

Factor Xa inhibitors from DuPont with potent antithrombotic activity in rabbits

Roche's novel 5-ht6 receptor ligands are broadly useful in treating CNS and neurologic disorders

Bristol-Myers Squibb identifies an optimized salt of a potent anti-HIV drug candidate

Bracco reports novel series of chelating agents for use in MRI

Welsh academic team studies inhibitors of retinoic acid metabolism for dermatology applications

Pfizer continues research into macrolide compounds

Duocarmycin derivative from Kyowa Hakko has potent antitumor activity, reduced toxicity

VIP analogues: a new neuroprotective approach to antiparkinsonian drug therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...